Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.
Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.
Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.
Keywords: SARI; burden; impact; respiratory infections; respiratory syncitial virus; surveillance.
© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.